Buy These 3 Blue-Chip Stocks After Strong Q2 2026 Earnings Results
Zacks reports that by July 24, 135 S&P 500 companies have posted Q2 2026 results, with total earnings up 67.8% year over year and revenue up 12.6%, while 87.4% beat EPS and 79.3% beat revenue estimates. It highlights three Dow blue chips with favorable Zacks Ranks: 3M (MMM), Travelers (TRV), and UnitedHealth (UNH), citing 2026 guidance and estimate revisions.
How this was made
The 30-second read
Why it matters
For each named company, the article provides specific Q2 performance drivers and, crucially, updated 2026 guidance or outlook metrics that can shift earnings expectations.
Market read
This is a company-specific earnings and guidance update roundup for three large US stocks, with explicit forward numbers that can drive near-term positioning.
What to watch
No discussion of valuation, balance-sheet risk, or detailed reserve/medical cost trend assumptions beyond high-level drivers; traders should verify whether estimate revisions reflect durable fundamentals or one-off effects.
Background
The piece summarizes early Q2 2026 earnings season results and then highlights three Dow blue-chips with favorable Zacks ranks.
Ticker impact
3M guides 2026 adjusted EPS to $8.80-$8.95, raised from $8.50-$8.70 projected earlier, alongside revenue growth above 4.5%.
Mild-to-moderate upside bias over days to weeks if the market is still digesting the earnings/guidance update.
The article provides explicit 2026 guidance uplift and specific operating drivers, but it is framed as a Zacks recommendation rather than a full earnings transcript.
Travelers reports Q2 strength and expects full-year 2026 underwriting expense ratio around 28.5%, with higher after-tax net investment income.
Neutral-to-positive reaction potential, with follow-through if investors focus on underwriting durability and capital returns.
The text includes concrete Q2 investment income details and a specific 2026 expense ratio, but lacks valuation or consensus comparison beyond estimate revisions.
UnitedHealth raises 2026 adjusted EPS guidance to $19.50-$20.00 from more than $18.25, citing margin improvement and Optum strength.
Likely supportive for the stock over the next several sessions, especially if investors weigh the guidance raise more than segment offsets.
The article provides explicit, time-relevant guidance numbers and identifies the key drivers and offsets, making it actionable for positioning.
Market effects
Broad insurer and healthcare/industrial earnings read-through: margin discipline, investment income, and cost management are emphasized as key swing factors.
Primarily US large-cap earnings season sentiment; could reinforce risk-on positioning in S&P 500/Dow constituents.
Limited direct global linkage in the text beyond general demand and fixed-income portfolio yield dynamics.
Counterpoint
The article is a promotional Zacks-style buy list; guidance raises may already be partially priced, and segment offsets (notably UNH Optum Health/Rx weakness) could cap upside.
Key entities
- company3M
Guidance raised for 2026 adjusted EPS to $8.80-$8.95; momentum in Safety and Industrial and restructuring savings cited.
- companyTravelers
Q2 results supported by catastrophe loss decline and higher net investment income; 2026 underwriting expense ratio outlook given.
- companyUnitedHealth Group
2026 adjusted EPS guidance increased to $19.50-$20.00; margin improvement attributed to Optum and pricing/cost management.
